What is Rallybio Corp?
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 88.03M, and a P/E ratio of 3.4x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.